VitaHEAT® Medical Announces the VitaHEAT™ UB3: Breakthrough Technology in Patient Warming

ROLLING MEADOWS, Ill., Jan. 12, 2016 /PRNewswire/ -- VitaHEAT^® Medical, LLC, a privately held medical device company, today announced the launch of the VitaHEAT^™ UB3 patient warming system. VitaHEAT UB3 is a breakthrough innovation in under-body patient warming using patented conductive ink technology in a thin mattress design. VitaHEAT UB3 is safe and effective, easy to use, and cost efficient. It is always on and can be used throughout all perioperative phases.

The VitaHEAT UB3 is easy to set up and operate. The thin mattress is virtually invisible to clinicians and allows full access to surgical sites. It is flexible, easy to clean, and completely portable. It is the only system on the market with both battery and plug-in AC options. VitaHEAT UB3 is also more cost efficient than forced-air systems. It is reusable and eco-friendly, with no disposables or red bag waste costs. 

"I have been very impressed with this system and how it aids in maintaining patient temperatures during surgery," said Dr. Lawrence Iteld, M.D., Chief of Plastic Surgery, Advocate Illinois Masonic Hospital. "It's always on and versatile enough to be used throughout all perioperative phases: in the ER, cath lab, dialysis and anywhere transfusions are administered."

"We have invested more than four years in developing the new VitaHEAT UB3 system. We are excited to offer this innovative solution that helps prevent patient hypothermia. Not only has our system been proven as effective as currently used forced-air patient warming solutions, it is safe and cost efficient," said Peter Farmakis, President and CEO of VitaHEAT Medical.

Hypothermia in patients is common during and after surgery. The incidence of hypothermia ranges from 60 percent to 85 percent in all postoperative patients when active warming is not used. The average postoperative hypothermia patient can cost the hospital up to $7,000, and has an extended length of stay by 2.6 days, on average. Mortality rates jump to 31 percent and wound infection rates jump to 19 percent when a patient becomes hypothermic.

In a recent clinical study, 94 percent of patients following 30 minutes of preoperative warming maintained normothermia, or a normal body temperature. Intraoperative patient warming reduces costs, recovery time and post-anesthesia care unit (PACU) stay.

VitaHEAT UB3 meets all FDA safety guidelines and has received 510(k) clearance. It has been engineered for safety with interactive sensors to actively monitor the correct temperature to keep patients safe. Independent heating zones provide more consistent control of the warming surface.

"Our focus is to continually bring new innovations for patient warming to market, with a goal of improving patient outcomes and reducing health care costs," said Farmakis. "We see the VitaHEAT UB3 as the first of many patient warming solutions that we will introduce over the next few years."

About VitaHEAT^® Medical, LLC
VitaHEAT^® Medical is a privately held medical device company dedicated to continually providing innovative patient warming solutions to reduce health care costs and improve patient outcomes. With more than four years of product development investment, 100 percent of VitaHEAT's focus is on patient warming. VitaHEAT products are developed and manufactured in the U.S.A. The company is headquartered in Rolling Meadows, Ill. For more information, please visit www.vitaheatmedical.com.

For more information, contact:

Amy Cummings
VitaHEAT Medical, LLC
[email protected] 
800-850-8350

SOURCE VitaHEAT Medical, LLC